School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Int J Nanomedicine. 2011;6:1611-9. doi: 10.2147/IJN.S23597. Epub 2011 Aug 9.
To deliver 2,3,5,6-tetramethylpyrazine (TMP) in a relatively large dose through a transdermal route and facilitate the practical application of microemulison in transdermal drug delivery.
The pseudo-ternary phase diagram for microemulsion regions was constructed using isopropyl myristate as oil phase, Labrasol(®) as surfactant, and Plurol(®) Oleique CC 497 as cosurfactant. A uniform experimental design was applied for formulation optimization. In vitro skin permeation experiments of six formulations were undertaken with TMP transdermal patch (EUDRAGIT(®) E100 as matrix) and TMP saturated solution as controls. We prepared TMP-oil dispersed in water-ethylene vinyl acetate-transdermal therapeutic system (TMP-O/W-EVA-TTS) with microemulsion as reservoir and EVA membrane as release liner; pharmacokinetic and brain distribution studies in rats were conducted with TMP transdermal patches as control.
The skin fluxes of TMP from microemulsions were 8.2- to 26.7-fold and 0.9- to 4.7-fold higher than those of TMP transdermal patch and TMP saturated solution, respectively, and were strongly affected by the microemulsion composition. The improvement in TMP solubility as well as the skin permeation enhancement effect of microemulsion components contributed mainly to transdermal delivery facilitation. In the pharmacokinetic study, the relative bioavailability of TMP-O/W-EVA-TTS was 350.89% compared with the TMP transdermal patch. Higher and more stable TMP contents in rat plasma were obtained after administration of TMP-O/WEVA- TTS than after application of TMP transdermal patch. In the brain distribution study, higher rate and extent of TMP distribution to brain, and lower rate of TMP clearance from brain were observed after transdermal administration of TMP-O/W-EVA-TTS than after application of TMP transdermal patch.
The novel transdermal delivery system prepared in this study showed a remarkable skin permeation improvement of microemulsion and facilitated its practical application in transdermal drug delivery. With this system as a vehicle, a relatively large dose of TMP could enable successful drug delivery via the transdermal route.
通过透皮途径给予较大剂量的 2,3,5,6-四甲基吡嗪(TMP),并促进微乳在透皮给药中的实际应用。
以肉豆蔻酸异丙酯为油相,Labrasol(®)为表面活性剂,Plurol(®)Oleique CC 497 为助表面活性剂,构建微乳区域的伪三元相图。采用均匀实验设计进行配方优化。采用 TMP 透皮贴剂(EUDRAGIT(®)E100 为基质)和 TMP 饱和溶液作为对照,进行 6 种制剂的体外皮肤渗透实验。我们制备了 TMP-油分散在水-乙烯-醋酸乙烯酯-透皮治疗系统(TMP-O/W-EVA-TTS)中,以微乳为储库,EVA 膜为释放衬垫;以 TMP 透皮贴剂为对照,进行大鼠药代动力学和脑分布研究。
TMP 从微乳中的皮肤通量分别比 TMP 透皮贴剂和 TMP 饱和溶液高 8.2 至 26.7 倍和 0.9 至 4.7 倍,并且强烈受到微乳组成的影响。TMP 溶解度的提高以及微乳成分的皮肤渗透增强作用主要有助于透皮传递的促进。在药代动力学研究中,与 TMP 透皮贴剂相比,TMP-O/W-EVA-TTS 的相对生物利用度为 350.89%。TMP-O/W-EVA-TTS 给药后,大鼠血浆中 TMP 的含量更高且更稳定,TMP 透皮贴剂给药后,TMP 清除率更低。在脑分布研究中,与 TMP 透皮贴剂给药相比,TMP-O/W-EVA-TTS 经皮给药后,TMP 向脑的分布速度更快、程度更高,TMP 从脑的清除速度更慢。
本研究制备的新型透皮给药系统显示出微乳显著的皮肤渗透改善作用,并促进了其在透皮给药中的实际应用。使用该系统作为载体,可以通过透皮途径给予较大剂量的 TMP,从而实现成功的药物输送。